Immunocorrective agent for treating diseases of viral aetiology |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Immunocorrective agent for treating diseases of viral aetiology (RU 2411039):
 2,3-seco-derivatives of betulonic acid / 2410390
Invention relates to novel chemical compounds of class of lupine 2,3-seco-triterpenoids. Obtained are 2,3-seco-derivatives of betulonic acid of general formula:
 Viral vaccine against marek's disease / 2410117
Viral vaccine contains cell-associated turkey herpes virus (THV) of "Vladimir" strain, cattle blood serum (CBS) and dimethylsulfoxide (DMSO) in ratio, wt %: 60.0÷80.0; 15.0÷25.0 and 5.0÷15.0 respectively. Strain is deposited in FGI VGNKI collection of microorganisms under registration number (reference) "Vladimir No 124-DEP" THV (further "Strain"). Strain is reproduced in culture of SPF-chicken embryo fibroblast cells (CFE) and reaches titre 3.5·106 PFU/cm3, for vaccine manufacturing used is suspension of infected CFE cells with titre not lower than 5.5·105 PFU/cm3.
 Medicinal agents with controlled release based on block-copolymers / 2409348
Invention discloses pharmaceutical composition for controlled release regarding toxic active compounds, in particular, bioactive proteins from class of interferons. Composition contains bio-degradable block-copolymer made of poly(ethyleneglycol)terephthalate (PEGT) in amount from 50 to 95%, and poly(butyleneterephthalate) (PBT). Agent may be represented as injection microparticles, injection liquid, capable of independent gel or solid implant formation. Besides, invention provides a pharmaceutical set, including specified composition, methods of composition making and pharmaceutical versions of its application.
 3,4-substituted 1h-pirazole compounds and their application as cyclin-dependant kinases (cdk) and modulators of glycogen synthase kinase-3 (gsk-3) / 2408585
Invention relates to compounds of formula
 Antiviral active component, pharmaceutical composition, medicinal agent, method of treating viral diseases / 2407738
Invention relates to novel antiviral active components which are substituted 2-aminomethyl-1-benzyl-1H-benzo[d]imidazoles of general formula 1 or pharmaceutically acceptable salts thereof, a pharmaceutical composition, antiviral medicinal agents, a method of preventing and treating viral diseases, especially those cause by hepatitis C virus (HCV). In general formula 1
Method for producing serum for treatment and prevention of viral intestinal and respiratory disease in calves / 2407543
Invention refers to veterinary virology. The method consists in the fact that antigens are produced with the use of bovine rednose virus of strain MVA (1)80 No.15 of infective activity 7.0-8.0 lg TCC50/cm3, bovine parainfluenza-3 virus of strain MVA (1)77 No.14 of infective activity 6.0-7.0 lg TCC50/cm3, bovine diarrhoeia - mucous disease virus of strain VK1-V1 genotype 1 of infective activity 4.5-5.5 lg TCC50/cm3, bovine rotavirus of strain RP-82 of infective activity 5.5-6.5 lg TCC50/cm3, bovine coronavirus of strain KP-83 of infective activity 5.0-6.5 lg TCD50/cm3. The viruses are purified and concentrated by adding barium sulphate in the final concentration 5-10%. A sedimented sorbent is separated by centrifugation. The virus is eluted from the sorbent by adding 0.2-0.25 M of sodium citrate. The prepared antigens are mixed in the volume ratios 1:(0.8-1.2):(0.8-1.2):(0.8-1.2):(0.8-1.2)):(0.8-1.2). Formalin in the final concentration 2.5-3.0% is added to bovine adenovirus of strain B-10 serotype 1 of infective activity 5.0-6.5 lg TCC50/cm3 and incubated for 24-30 hours at 36.5-37.5°C. Then aluminium hydrate is added to produce a bovine adenovirus strain V-10 serotype 1 antigen. Then, the producers are triply hyperimmunized separately with the mixed antigens and bovine adenovirus strain V-10 serotype 1 antigen in two points. On the 7-10th post-hyperimmunisation day, the producers' blood serum is analysed for antibody titres. The producers' blood is drawn in certain antibody titres. Then, the producers' serums prepared with the mixed virus antigens are combined with the serum prepared for the bovine adenovirus strain V-10 serotype 1 antigen at 1:(0.8-1.2) respectively. The end product is preserved by adding merthiolate in the final concentration 0.01-0.02 %.
Associated vaccine against sheep pox and plague of small ruminants / 2406535
Invention relates to field of veterinary. Vaccine contains suspension of culture vaccine strains "Б"/5-96 of sheep pox virus and 45G37/35-K of small ruminants plague virus with activity not less than 4.5 Ig TCD50/cm3, lactose-peptone or succhrose-gelatin stabiliser and demineralised water with the following component content, vol %: vaccine strains "Б"/5-96 of sheep pox virus 22.0-27.0, vaccine strain 45G37/35-K of small ruminants plague virus - 22.0-27.0, lactose-peptone or succhrose-gelatin stabiliser- 40.0-44.0, demineralised water - the remaining part.
 Methods for preparing acyclovir formulation / 2406504
Present invention refers to chemical-pharmaceutical industry, and concerns a method for preparing acyclovir formulations of better biological availability. Also the invention refers to a unit dosage form of acyclovir, a mode of administration, a method of treating a viral disease, and a method of improving biological availability of acyclovir.
 Imidazopyrazines as tyrosine kinase inhibitors / 2405784
Present invention refers to new imidazopyrazines of formula
Drug preparation for prevention and treatment diseases of viral etiology in cattle and method of such diseases prevention and treatment / 2404807
Invention relates to the field of veterinary medicine. The drug preparation includes a polyvalent serum against infectious bovine rhinotracheitis, parainfluenza-3, virus diarrhea and adenoinfection in cattle, and immunostimulant Vivaton in the following ratio, wt %: polyvalent serum against infectious bovine rhinotracheitis, parainfluenza-3, virus diarrhea and adenoinfections of cattle - 80-85, Vivaton - the rest. The drug preparation is administered subcutaneously to calves: for diseases prevention - twice with an interval of 10-14 days at a dose of 0.5 ml/kg of body weight, at that the first injection of the drug to calves is carried out during 24 hours after birth or admission to the farm unit, and for medical purposes the drug is administered at a dose of 1 ml/kg of body weight twice with an interval of 48 hours, and to adult animals the drug is administered subcutaneously at a dose of 20.0 ml twice with an interval of 7-14 days.
Pharmaceutical agent / 2410094
Invention concerns a pharmaceutical agent in the form of a solution for injections containing Mexidol, sodium metabisulphite as a preserving agent which can be used for treating an acute myocardial infarction, vegetovascular dystonia, psychosomatic and some other diseases. The pharmaceutical agent exhibits high storage stability provided a pH value of the solution is maintained at 4.2-4.4. Preferentially, the pharmaceutical agent is packed in dark glass ampoules of nominal volume 2 ml or 5 ml.
Syrup pharmaceutical composition and method for producing thereof / 2410088
Invention refers to manufacturing drugs in the liquid dosage forms, namely in the syrup dosage form containing propylene glycol, sodium benzoate, sodium citrate, pentosesquihydrate, riboflavin, citric acid monohydrate, edible sorbite, aromatiser and purified water. An active substance can be presented with paracetamol exhibiting analgetic and antipyretic action, promoting elimination of such symptoms, as a moderate pain and high temperature, as well as ambroxol exhibiting expectorative and mucolytic action.
 Ophthalmic compositions and methods of treating eyes / 2410081
Ophthalmic composition contains a water carrier ingredient and an effective amount of at least one compatible soluble substance for eye surface protection against hyperosmotic stress where the compatible soluble substance is chosen from a group consisting of carnitine and erythrite. The ophthalmic composition has osmolarity in the range 200 to 1000 mOsmol/kg. Also, the ophthalmic composition can contains glycerine and carboxymethyl cellulose, a preserving agent. The ophthalmic composition delivers compatible soluble substances to eye surface cells to counterbalance an osmotic stress thereon. The composition is applied for manufacturing a drug for eye surface protection against hyperosmotic stress. A method of treating human dry eye keratitis involves administration of said composition.
Method for producing bicarbonate dialysis fluid / 2410080
Dialysis solution contains the following components, in mmol/l: Sodium chloride NaCl 137.0-139.3; Calcium chloride CaCl2·2H2O 1.2-2.5; Magnesium chloride MgCl2·6H2O 0.5-1.0; Potassium chloride KCl 0.3-4.0; Hydrochloric acid 2.0-4.0; Sodium acetate 0-0.3; Glucose, g/l 0-5.0; Sodium bicarbonate 32.0.
Agent to correct stress conditions in animals / 2409347
Invention relates to veterinary science, namely to stress correctors and adaptogens for animals. Preparation for correction contains selenium in nanosize condition and zero valency (Se0) , ascorbic acid and water for injections, at the following ratio of components in wt %: selenium (Se0) 0.001-1.0; ascorbic acid 5.0-20.0; water for injections - balance.
 Chinese medicinal composition, method for preparing and administration / 2408384
Medicinal composition for treating cerebral ischemia and senile dementia contains 1-10 weight parts of ginseng root, 1-10 weight parts of ginkgo leaves, 0.05-0.5 weight parts of saffron snouts and 5-10 weight parts of soya bean; said ginseng root, ginkgo leaves, saffron snouts and soya bean can be presented in the form of raw vegetable materials or extracts prepared by extraction of the raw vegetable material in the same amounts. At least double amount of 60-80 % ethanol is added to ginkgo leaves, and immersing extraction is carried out at 50-70°C at least once to produce liquid extracts; the liquid extracts are mixed and concentrated to enable relative density of the produce liquid concentrate to reach approximately 1.05; water is added to the liquid concentrate, and the prepared mixture is filtered to produce a filtrate; the filtrate is chromatographed on polar macroporous adsorption styrene resin in a protonation form; resin and drug substances are eluted with water and 60% ethanol; an aqueous eluent is discharged, while an ethanol containing eluent is collected and concentrated to eliminate alcohol odour and to produce a concentrated eluent; water is added to the concentrated eluent, and said mixture is filtered to prepare another filtrate; the filtrate is chromatographed on weakly polar macroporous adsorption styrene resin; resin and drug substances are eluted with water, 15% ethanol and 60% ethanol, respectively; the aqueous eluent and 15% ethanol eluent are discharged, while 60% ethanol eluent is collected. The inventions allow implementing specified object matters.
Inhalations of nonsteroidal anti-inflammatory drugs in treating acute and chronic bronchitis / 2408376
Inhalation of the nonsteroidal anti-inflammatory drug lysine acetylsalicylate with using a nebuliser applicable in inhaling therapy for treating chronic obstructive pulmonary disease or emphysema is offered.
Method for stabilising thiamine chloride and thiamine bromide solutions / 2408374
Invention refers to pharmaceutical industry, namely to drug stabilising agents, namely stabilising 2.5% and 5% thiamine chloride, 3% and 6% thiamine bromide with a combined antioxidant containing 9.5 mcM of unithiol and 14 mcM of cycvalon.
 Pharmaceutical composition containing docetaxel and degradation inhibitor and method for preparing thereof / 2408362
Invention refers to medicine, namely a pharmaceutical composition containing Polysorbate 80, anhydrous docetaxel (I) or its trihydrate and organic acid used as a degradation inhibitor and characterised by pH value within 2.5-4.5.
 Local nail compositions / 2408361
Group of inventions refers to medicine, namely to dermatology, and can be used in pathological state of nails. A method of treating wherein a first composition containing a reducing agent of potential more than +20 mV and a second composition containing an oxidising agent of potential less than -50 mV are used. The compositions are applied to coat a nail separately consistently with the first composition applied in the beginning, and then the second composition. Either the first, or second, or third compositions which is a separate option for the compositions with the restoring and oxidising agents, containing a medicinal agent. Also, there is offered a kit comprising the first and second compositions which are arranged separately, and the medicinal agent which is included either in the first composition, or in the second composition, or optionally in the third composition.
Prophylactic agent for skin with antituberculous effect / 2409367
Invention relates to prophylactic agent for skin, having antituberculous effect, which includes the following active substances - 0.50-0.75 wt % of streptomycin and 7.0-10.0 wt % of stabilised sol of silver nanoparticles, and also polyethylene oxides (PEO) of brands 400 and 1500 as the base.
|
FIELD: medicine, pharmaceutics. SUBSTANCE: invention refers to pharmacology and medicine. Substance of the invention consists that an immunocorrective drug exhibiting an intense specific antiviral activity for treating diseases of viral aetiology contains human recombinant interferon alpha and/or beta, and/or gamma, an antioxidant complex of tocopherol acetate or its derivative, including water-soluble ones, and ascorbic acid salts, calcium pantothenate, antiviral ingredients, as well as pharmaceutical aids and excipients in certain ratios in 1 g of the drug. As antiviral ingredients, the drug contains arbidol and its derivatives, remantadin, oseltamivir, ribavirin, inosine pranobex (isoprinosine), glycyrrhizic acid and its derivatives, nucleosides of a group - famvir, valacyclovir, ganciclovir, valganciclovir, foscarnet, cidofovir, lobucavir, sorivudine, brivudine, antiretroviral - lamivudine, zidovudine, lopinavir, stavudine. The agent is presented in rectal and vaginal suppositories, gel, ointment, liquid. EFFECT: invention provides higher therapeutic effect and high bioavailability for treating the diseases of viral aetiology. 5 cl, 17 ex
The invention relates to the field of medicine and pharmacology, and relates to the creation of a new tool for a wide spectrum of action on the basis of human recombinant interferon for the treatment of diseases of viral etiology. Currently, the proportion of viral diseases is up to 80% of all infectious diseases. The treatment of these diseases is fraught with many difficulties and because of the biological characteristics of the pathogen (intracellular multiplication of viruses using genetic apparatus of the host, in particular, human), due to the nature of the pathological process caused by these pathogens. The most common viral infections are respiratory infections: influenza, characterized by the epidemic (pandemic) disease other viral respiratory infections, different mass seasonal outbreaks, caused by a variety of viruses (adenovirus, rhinovirus, respiratory syncytial, paragraphstyle viruses, coronaviruses and others). In our country each year to 30 million cases of flu and ARVI (this only applied to the doctor). Acute gastrointestinal disease (AII) always take 2nd place on the prevalence of infections (up to 600 thousand cases per year), with up to 80% of diseases caused by varusmiespalvelu share amount and herpes virus infection: viruses in this group are involved in various severity of clinical manifestations and consequences of diseases. In recent years, driven by increases in the incidence of viral hepatitis, mainly parenteral (hepatitis b, D, C). Identified several new types of parenteral hepatitis G, TTV, Sen etc, are candidates for new types. Increasingly, registered chronic, recurrent, persistent forms of many viral infections that occur on the background of immunodeficiency (herpes 1, 2, 3, 4, 5, 6, 7, 8 types of human papillomavirus infection, parenteral hepatitis, HIV etc), which are the most difficult to treat, often not fully cured: pathogen remains for life in the body of the patient. Almost all viral infections can be transmitted in utero, leading to various forms of pathology of the fetus, until his death. The feature of viral infection is intracellular multiplication of viruses causes a low efficiency of many antiviral drugs, because, often, viruses are simply unattainable for many of them, requiring increased doses of the drug. While antiviral drugs act and the healthy cells and damage them, leading to functional impairment of cells, tissues and organs, causing the appearance of side effects, often very heavy. This, in turn, leads to the need to replace the drugs, the timing of those is FIPA etc. Reduction in side effects and their severity, as a rule, can be achieved by using complex therapy: selected unidirectional drugs with different mechanisms of action. Thus can be achieved by additive and/or synergenic effect when using lower doses of each drug. In addition, in complex therapy it is advisable to use drugs, contributing to the weakening or reducing the side effects of antiviral therapy: vitamins, antioxidants, antihypoxants, membrane stabilizers, hepatoprotectors, detoxifying, as well as drugs, promoting regeneration, repair of tissues and organs and stimulating the protective forces of the organism itself. Equally important is the use of drugs: from the characteristics of the route of administration of the drug depends largely not only tolerability, and therapeutic efficacy. It is well known that the application of drugs inside the most often recorded side effects gastro-intestinal tract (exacerbation of gastritis, the appearance of erosions, ulcers, toxic effects on the liver, kidney, human microflora of the mouth, intestines, vagina). Parenteral drugs have problems not only with the liver, the kidneys, but also to shelter the dancers, reproductive organs, etc. When these routes of administration used drugs are at greatest negative influence of the enzymatic systems of the gastrointestinal tract and liver. In connection with the above more preferable in many cases is the rectal route of administration because it is noninvasive, provides less degradation of drugs from the effects of enzymatic systems. It is known that farmacocinetica drugs introduced rectally, almost completely the same as that for parenteral administration, including the speed of delivery of drugs into the bloodstream. Currently, there are a huge number of antiviral drugs that have been widely used in the treatment of diseases of viral etiology. However, as already mentioned, the features of the pathogenesis of viral infections cause significant difficulties in the treatment of these diseases. Most commonly in the treatment of respiratory diseases used drugs such as Arbidol (or its derivatives), rimantadine, amantadine, oseltamivir, ribavirin, and other Arbidol and its derivatives inhibit the influenza viruses types a and b, preventing the fusion of the lipid envelope of the virus with the cellular membranes upon contact of the virus with the cell, showing interfereing carousel activity stimulate humoral and cellular immune responses, the phagocytic function of macrophages, increases the body's resistance to viral infections. The effectiveness of Arbidol and its derivatives and other acute respiratory infections. Oseltamivir - belongs to the most modern anti-influenza drugs. It inhibits the neuraminidase of influenza virus types a and B. This enzyme catalyzes the process of release of newly formed virus particles from infected cells, their penetration into the cells of the epithelium of the respiratory tract and further spread of the virus in the body. The effectiveness of oseltamivir not depends on the type of influenza virus that is very important for the emergence of new epidemic variants of influenza virus strains, including avian influenza viruses (H5N1, H5N2). Rimantadine (a derivative of amantadine) is effective in the treatment and prophylaxis of influenza type A. It blocks the incorporation of viruses into host cells, inhibits the early stage of reproduction of viruses that selectively inhibits the synthesis of viral RNA and protein, not inhibiting RNA synthesis in normally functioning cells, induces interferon production, increases the functional activity of lymphocytes. Rimantadine together with Arbidol used for the treatment and prophylaxis of influenza type a proven additive and synergenic effect in the n conjunction the use of these drugs on laboratory models. Rimantadine shows activity against parainfluenza viruses, mumps, reoviruses, oncogenic RNA viruses (papilloma viruses), and DNA-containing viruses: viruses of the herpes group, including varicella, adenovirus, and arenaviruses, Hantaviruses, viruses group pox, Marek's disease, shows the effectiveness of ribavirin and against causative agents of viral hepatitis a, b, C (the most active against hepatitis C virus). Large group of herpesvirus infections includes 8 types of viruses - these viruses, pantropy that can affect almost all organs and systems of the human body. The herpes simplex viruses type 1 and 2 affect the mucous membranes and the skin, the cause of genital herpes, herpes encephalitis, and intrauterine lesions of the fetus. The virus varicella - zoster cause the same disease. Epstein-Barr is an etiological factor of infectious mononucleosis, Burkitt lymphoma, nasopharyngeal carcinoma, leukoplakia. Cytomegalovirus causes of congenital lesions of the Central nervous system, retinopathy, hepatitis and other herpes Virus type 6 is lymphotropic virus, herpes virus 7 type associated with chronic fatigue syndrome, herpes virus 8 type - with Kaposi's sarcoma and lymphoproliferative diseases. In the Rus of this group are widely distributed among the people in all countries of the world. When carrying out screening assays for antibodies to herpes simplex virus type 1 positive results found in 90-95% of the adult population, the virus late CMV antibodies are found in 60-70% of adults. Herpes simplex virus type 2 plays a role in Association with papovaviruses in the development of neoplastic processes, in particular cervical cancer, may act as a cofactor in carcinogenesis, initiating the development of dysplasia. According to the who mortality caused by the herpes simplex virus, ranks second after influenza. The above can consider herpes virus infection and struggle with it important social health problem. In addition, exacerbation of herpes infection during pregnancy often leads to intrauterine infection of the fetus. It is proved that chronic, persistent form of the disease is always associated or primarily due to differing according to the degree of immune system disorders and treatment of these diseases should be carried out comprehensively: antiviral drugs together with immunokorrigiruyuschy means. In the practice of public health is currently used for a wide range of anti-herpes drugs. One of the first - acyclovir, it is used currently. However, there are a huge number of new Bo is her perfect and more active drugs: valacyclovir, famvir, ganciclovir, valganciclovir, foscarnet, ribavirin, cidofovir, lobucavir, sorivudin, brivudin, penciclovir, inosine pranobex, etc. it is known that all cyclic nucleosides used to treat herpes infections, inhibit only the active replication of herpes viruses, therefore the exchange rate using drugs in this group will not prevent recurrence of the disease or infection related or a new type of herpesvirus. All this underlines the importance of the complexity of this problem and confirms the need to further develop not only the treatment, but the development of new complex products for the treatment of herpesvirus infections and mandatory use of immunocorrective therapy. Among viral infections of man are distinguished by characteristic clinical manifestations of the disease caused by papilloma viruses, These viruses infect the anogenital region, are sexually transmitted and cause the formation of benign and malignant tumors. Today there are about 70 types of human papilloma virus (HPV), more than 10 of them belong to the group of high-risk oncogenic diseases. The virus is transmitted to newborns during childbirth. The most likely rising infection. There is evidence that HPV infection leads to increased abortions. P is also shown, that recurrent juvenile papillomatosis of the larynx is also associated with intrauterine infection of the fetus in the presence of the virus HPV in pregnant women. Treatment of these patients includes surgical and therapeutic measures. However, a very important point is the need to prevent infection of the newborn and taking the necessary measures before delivery. An even more difficult issue, because of the severity of the clinical course, is the issue of treatment of viral hepatitis b, D and With other parenteral hepatitis. Liver is the main detoxification organ is always accompanied by serious consequences, restoration of functional activity of this organ is often problematic. The incidence of parenteral viral hepatitis in our country is growing from year to year. Annually in the world die from the effects of parenteral hepatitis at least 2 million people. Proven vertical transmission of parenteral viral hepatitis. In different countries, from infected mothers become ill from 3 to 28% of newborns. Treatment of hepatitis by using drugs of different groups, aimed at different parts of the pathological process: antiviral agents, immunomodulatory, hepatoprotective, membrane, detoxifying, etc. Of antiviral ol the drug are widely-used drugs adefovir dipivoxil, lamivudine (zeffix) is the most effective for hepatitis b ribavirin - active hepatitis C. Ribavirin is highly active antiviral drug most broad-spectrum used in medical practice today. It is known that interferon increases the phosphorylation of ribavirin, causing the synergistic action of these drugs in some cases. There are also data on the effectiveness of glycyrrhizic acid and its derivatives in the treatment of viral hepatitis. Glycyrrhizin acid and its derivatives (giarratana acid, glycerinate, glitsiram and others) possess antiviral activity, inhibit phosphorylation of cellular and encoded virus protein in virus infected cells, inactivate viruses outside the cells, blocking the introduction of viral particles into the cell and interfere with the ability of the virus to the synthesis of new structural components. The highest activity is in relation to viruses of the herpes group, different types of HPV, including HPV. The local application have high trapnest to cells infected with virus, accumulate in the lesions, mutually reinforce the effect of other antiviral drugs. Have anti-inflammatory activity, induce the formation of interferon. Recently widely COI the box is used inosine pranobex (isoprinosine). This drug also possesses immunomodulatory and antiviral activity, is effective in diseases herpes type 1 and 2, herpes zoster, infection with the Epstein-Barr severe forms of infectious mononucleosis and other viral infections. Antiviral drugs if necessary, used in conjunction with interferon in high doses: high-dose interferon inhibit virus replication. The diversity of pathogens of viral origin, the diversity of clinical manifestations of diseases caused by viruses, the severity of the disease and the impossibility of complete elimination of viruses in chronic, persistent forms of the disease, in which the virus for life is stored in the body, reflects the complexity and importance of the fight against viral infections. It is proved that a significant, if not major, role in the course of diseases of viral etiology plays immune system: chronic infectious process, lifelong persistence of many viruses, relapsing course, activation of the infection during pregnancy, etc. is the consequence of failure of protective forces of an organism. From the above it is obvious that both antiviral and immunomodulating therapy should be used together, not only in the treatment of such patients, but in the si is the subject pregravidarnoy training with the purpose of prevention of intrauterine infection of the fetus, as well as in the preparation of pregnant women for childbirth. Obvious and the need for development of new complex products, taking into account the pathogenetic features of viral infections to treat them. The drug must possess not only an antiviral, but immunomodulator, membrane, hepatoprotective, detoxifying and desensitizing activities, as well as to reduce the number and severity of side effects. From immunokorrigiruyuschy drugs the most studied and widely used in the practice of health care in our country and abroad interferon preparations. Interferons are polyfunctional low molecular weight proteins, possess immunomodulatory, antiviral and antibacterial effects. The most widely used interferon preparations for parenteral use. Currently, however, uses a large amount of dosage forms for local, rectal, vaginal use. Known drug (patent RU 2187331), made in the form of solid dosage forms in the form of tablets coated with acid-resistant or water-soluble shell. Means of complex composition, including interferon and ribavirin. The method of application, area of use, the mechanism of the drug completely otlichautsya stated. Known drug (patent RU 2187332) on the basis of interferon and other cytokines and immunomodulators, including chemical nature, in combination with antibiotics, antianginalnami, Antiprotozoal, a number of other components and ribavirin. Integrated part of the specified funds differs from the stated us. As you know, pharmacokinetics and pharmacodynamics fully depend on the composition of the drug, the contribution of each component and their interactions that define the essence of action of the drug. Known means (patent RU 2255735), made in the form of liposomal drug ribavirin in dried form. This tool is a monotherapy and has the properties of a single ribavirin. Known drug Viferon (patent RU №2024253)containing genetically engineered interferon Alfa-2, the antioxidants ascorbic acid and alpha-tocopherol. It is shown that the specific activity of the interferon increases significantly in the presence of antioxidants. This drug is taken as the nearest equivalent. However, this tool does not have the breadth of range, because it has no specific antiviral activity that necessitates the use of additional antiviral therapy. The task of the invention is the creation of new immunocorrective tools with a high degree of bioavailability of the interferon-based anti-oxidant complex having expressed specific antiviral activity due to the introduction of antiviral drugs, detoxification, hepatoprotective, antihypoxant, antioxidant, lipoic effects for the treatment of diseases of viral etiology, as well as additional components that enhance the effectiveness of the drug for the treatment of diseases of viral etiology. The technical result is to develop a new immunokorrigirujushchej means having a pronounced antiviral activity for the treatment of acute, chronic, relapsing disease of viral etiology, providing a higher therapeutic effect by introduction of highly active antiviral drugs, use synergize active components, increase bioavailability and reduce the side effects by the introduction of substances with liquid pentrant Dammam, as well as detoxification, hepatoprotective, antihypoxant, antioxidant, lipoic properties. This technical result is ensured by the fact that the product contains human recombinant interferon alpha and/or beta and/or gamma and antioxidant complex of tocopherol acetate and its derivatives, including water-soluble forms and salts of ascorbic acid, calc what I Pantothenate, anti-virus components from a number of Arbidol or its derivatives, rimantadine, oseltamivir ribavirin, an inosine pranobex (isoprinosine), glycyrrhizin acid and its derivatives, nucleosides - famvir, valacyclovir, valganciclovir, ganciclovir, foscarnet, cidofovir, lobucavir, sorivudin, brivudin, antiretroviral - lamivudine, zidovudine, lopinavir, stavudine, and auxiliary substances and formative components and made in the form of a rectal-vaginal suppositories, ointments, creams, gel, liquid at the following ratios of 1 g dosage form: Human recombinant interferon alpha
Sodium ascorbate or calcium, or
Interferon is a polyfunctional low molecular weight protein, has distinct immunokorrigiruyuschy properties, antiviral and antibacterial, and antiproliferative activities. The antiviral effect of interferon caused by intracellular action at the stage of virus replication on m-RNA (inhibition of transcription and translation leads to cessation of viral replication). However, outside the cell, the virus is not available for interferon. The peculiarity of interferon is the dependence of its effects on the dose: when using small and medium doses more pronounced immunomodulatory, regenerating, anti-virus, anti-bacterial oposredovannoe actions. High-dose interferon determine antiproliferative, antiviral effects, which are used in Oncology and severe viral infections, including lesions of the internal organs, the Central nervous system, etc. However, when high doses of interferon has no immunokorrigiruyuschy effect. Tocopherol acetate and its derivatives in combination with ascorbic acid or its derivatives are vitamins and belong to the group of funds that regulate metabolic processes. They have antioxidant properties, limit the damaging effects of lipid peroxidation, stabilize the gunning membrane. Proven synergene action of these components when used together, enhancing the antiviral activity of interferon. Integral part of the comprehensive tools is calcium Pantothenate, with antitoxic action that is most valuable in the treatment of such chronic diseases as hepatitis, herpes encephalitis, destruction of internal organs in cytomegalovirus processes, diseases of mononucleosis, lymphoproliferative processes, caused by the Epstein-Barr etc. Introduction to complex means of specific antiviral drugs provides targeted action on the etiological factor. Are drugs with different mechanisms of action in conjunction with interferon, contributing to the antiviral effect due to the implementation of other mechanisms and immune correcting actions allow you to get incomparably higher therapeutic effect. The use of antiviral drugs in conjunction with interferon, due to their diverse actions on the disease process, can reduce the dosage of active ingredients, providing thus a reduction in the number and severity of side effects typical of chemicals. Example 1
Example 2
Example 3
Example 4
When herpes diseases, as proven what waves the virus persists in the body and marked man for life. The goal of treatment is to stop the escalation and restore the protective forces of an organism of the patient. In practical work it is currently used quite a wide range of cyclic nucleoside drugs with anti-herpes activity. However, as mentioned above, these drugs inhibit only the active replication of herpes viruses and cannot prevent relapses. All this underscores the need for development of new complex products for the treatment of herpesvirus infections with regard to violations of the immunological status: immunomodulatory drugs help to reduce exacerbations, increase the time of remission. Example 5
Example 6
Example 7 (suppositories, liquid, gel)
Example 8 (suppositories, gel, ointment)
Example 9 (suppositories)
Herpes, papilloma viral infection, like almost all viral infections, especially chronic, persistent form, are transmitted in utero, causing various forms of pathology of the fetus, up to stillbirth. It is therefore extremely important are the issues of treatment of pregnant women for the prevention of transmission to the fetus and pregravidarnoy training for women. Combination preparations of interferon with antioxidants and antiviral drugs useful in solving these problems. Example 10 (suppositories, ointment, gel, liquid)
Should indicate that the antiviral drugs in some cases have toxicity. However, the inclusion of additional components in complex shapes can reduce the risk of side effects and significantly improve the efficiency of therapy compared with monotherapy, traditionally used in medical practice. As mentioned above, the greatest difficulties experienced by physicians in the treatment of patients with chronic viral hepatitis, and severe forms of diseases hepatitis C and mixed infections, especially HIV. When hepatitis b is the most widely used - lamivudine in hepatitis C, ribavirin. The use of these drugs in combination with interferon, antioxidants and detoxifying ingredients - calcium Pettinato, glycine, glutamic acid from membrane and hepatoprotectors - is reasonable and allows you to work on a wider range of pathogenetic links of the chain. While the inclusion of the drug as auxiliary substances phospholipids, which are hepatoprotectors, membrane stabilizers, and amino acids (glutamic acid, glycine, lysine) also allows you to improve the condition of the liver, helps the absorption of vitamins and other nutrients. Introduction phospholipids together with the surface and the active substances increases the bioavailability of drugs with any method of introducing them due to emulsification and increase the permeability of membranes, mucous membranes and skin. These same properties are also used by us tween-80, tween-60, spiny, sodium laurylsulfate, sodium tamilselvam, sodium sterilant, glycerin and other The use of amino acids contributes to the stabilization activity of interferon. In addition, amino acids have antioxidant properties, increase the body's resistance to hypoxia (antihypoxants), improve metabolic processes. Glycine has an antioxidant effect, helps to restore damaged tissues, has a positive effect with muscular dystrophy. Glutamic acid also has the effect of detoxification, increases resistance to hypoxia is hepatoprotector. Lysine prevents deposition on the walls of blood vessels lipoproteins, has an antiviral effect, is involved in the synthesis of antibodies. Calcium Pantothenate enters the body in Pantothenic acid, which is an integral part of coenzyme A, is involved in the metabolic processes of the organism, normalizes cellular metabolism, also has an antioxidant effect, helps to normalize intestinal. Example 11 (suppositories)
Example 12 (suppositories, liquid, gel)
Example 12 (suppositories, liquid, gel)
As mentioned above, when creating a soft dosage forms uses a number of auxiliary substances, which provide the necessary physico-chemical properties, however, many of these components contribute to the improvement of penetration h is cut skin or mucous coverings, a more complete release of the active components of the drug, as well as preserving the physical and biological properties of the dosage form. To stabilize the activity of the drug can be used in addition to the above amino acid stabilizers selected from a number of high-molecular compounds: dextrans, polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol. As preservatives, ensuring the microbiological purity, can be selected substances from the series: benzalkonium chloride, gasoline, alcohol, benzoic acid, sorbic acid, parabens. Together, these components allowed us to obtain a product with desired properties. The use of these components is shown in the following examples: Example 13 (suppositories)
Example 14 (suppositories, gel, liquid, ointment)
Formative components can be selected from the range: hydrophobic base for suppositories - cocoa butter, hard fat or hydrogenated fats (Kuva 300, 500, 900, or Packer-21, or Maspol, or Witepsol, or Labopol, or Hisomel 100, 500) or other similar fats. Hydrophilic base - derivatives of cellulose, collagen, gelatin, polyethylene oxides, polymers and copolymers of acrylic and methacrylic acids. Debilnye basics - oxides with solid fats. Make suppositories, ointments, gels, liquid traditional method (Pharmaceutical technology, 2nd edition, Publishing center "Academy", Moscow, 2006). The following examples illustrate embodiments of the invention. Example 15 (suppositories, ointment).
Example 16 (suppositories, ointment)
Example 17 (suppositories, gel, liquid)
Developed a new drug is immunocorrective drug interferon-based anti-oxidant complex, which has expressed specific antiviral activity due to the introduction of antiviral drugs desintoxicacion, hepatoprotective, antihypoxant, antioxidant, lipoic effects with a high degree of bioavailability for the treatment of diseases of viral etiology. Stated the vehicle was studied in cell culture models and laboratory animals. Researched anti-influenza action of the drug on the culture of cells infected with influenza virus a H3N2 strain. In monoclonal culture of MDCK cells for 24 hours before infection with the virus contributed extract suppository (recipe No. 1) in dilutions (two-fold dilution was made in the environment of the Needle), and in cell culture for comparing performance contributed extract Viferon (suppozitornoj form). Control is Laila pure cultures of cells, which was made only nutrient medium Needle. After 24 hours contributed influenza virus in a certain dose of all wells with cell culture, in addition to the control cell culture. Records produced by the cytopathic effect of the virus. In the result, it was shown that in untreated preparations holes all cells were killed. In the hole that was previously made interferonsource extract of the drug Viferon, killed 60% of the cells. In cells treated with the claimed means by recipe No. 1, died only 30% of the cells. This shows a higher efficiency funds. On the model of herpetic infection in rabbits (herpes simplex virus type 2 is rubbed in the mucous membrane of the genital organs of males) studied the prophylactic and therapeutic effect of the suppositories by recipe No. 7 in comparison with the drug Viferon. Control group animals were injected any drugs. Profilakticheski effect was investigated in three groups of rabbits 5 pieces in each group. All the animals of the experimental group and the comparison have entered the appropriate preparations for the day before infection. One day all the animals were infected by the herpes virus as indicated above, including the control group, which did not enter the drugs. Immediately after this procedure, the animals of the experimental group and group sravnenie is introduced suppositories on these formulations. Drugs continued to enter for 5 days (2 times a day) and exercised daily monitoring of mucous in all animals. After two days all the infected control animals (which did not enter any of the claimed means or Viferon) were detected bubble rash that on the following day in most cases passed erosion polymorphic in shape and size. At the same time from 5 animals receiving the claimed means of only two identified isolated elements with no tendency to erozirovanne. The receiving Viferon detected the appearance of the rash and erosion in 3 animals. Thus, the claimed tool proved to be more than the comparator drug, as a preventive measure. therapeutic effect was studied on similar groups of animals: all animals of the experimental group (declared medium), comparison group (Viferon) and control (received no drugs) suffered a virus on the mucous membranes of the genitals and on the second day, when there was clinical manifestations of varying degrees of severity with isolated erosions, animals of the experimental group and the comparison group began to enter suppositories (twice a day). As a result, the fifth day of observation were marked differences in the severity of infection: in the animals receiving the x declared the tool, clinical manifestations of infection were significantly less pronounced. In these animals, almost all of erosion were in the process of epithelialization, bubble lesions remained at 1 individuals. In the group with Viferon erosion were noted in 3 individuals, along with kapitalizirovana. In animals not receiving the drugs, all were manifestations of herpetic erosive process in stages of varying severity. The results obtained indicate the presence of a more pronounced therapeutic effect funds model of acute viral infections - the Herpes Simplex infection. 1. Immunocorrigirutee drug, which has expressed specific antiviral activity for the treatment of diseases of viral etiology, characterized in that it contains human recombinant interferon alpha and/or beta and/or gamma, anti-oxidant complex of tocopherol acetate and its derivatives, including water-soluble, and salts of ascorbic acid, calcium Pantothenate, anti-virus components, as well as supporting and shaping components in the following proportions per 1 g of the drug:
2. The drug according to claim 1, characterized in that it includes as antiviral components - Arbidol and its derivatives, rimantadine, oseltamivir, ribavirin, an inosine pranobex (isoprinosine), glycyrrhizinic acid and its derivatives, nucleosides from a number - famvir, valacyclovir, ganciclovir, valganciclovir, foscarnet, cidofovir, lobucavir, sorivudin, brivudin, antiretroviral - lamivudine, zidovudine, lopinavir, stavudine. 3. The drug according to claim 1, characterized in that as excipients contains phospholipids - phosphatidylinositol, phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, amino acids - glutamic acid is, lysine, glutamine, surfactants and penetrants - tween-80, tween-60, spiny, sodium laurylsulfate, sodium tamilselvam, sodium sterilant, glycerin, stabilizers selected from a number of high-molecular compounds: dextrans, polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol and/or glycine, or glutamic acid and preservatives are benzalkonium chloride, benzyl alcohol, benzoic acid, sorbic acid, parabens. 4. The drug according to claim 1, characterized in that it includes a forming substance: a hydrophobic base for suppositories - cocoa butter, hard fat or hydrogenated fats - Kuva 300, 500, 900, or Packer-21, or Maspol, or Witepsol, or Labopol, or Hisomel 100, 500, or other similar fats, hydrophilic base - derivatives of cellulose, collagen, gelatin, alginates, polyethylene oxides, polymers and copolymers of acrylic and methacrylic acids, debilnye basics - oxides with solid fats. 5. The drug according to claim 1, characterized by the fact that made in the form of a rectal-vaginal suppositories, gel, ointment, liquid.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||